Specifically, this protein was evaluated in cells in which F3 peptide-targeted drug combinations enabled higher cytotoxicity relative to targeted liposomes containing DXR alone, namely ovarian cancer SKOV-3 cells (Figure 4 and Table S3), triple-negative breast cancer MDA-MB-231 and nucleolin-overexpressing (positive control) MDA-MB-435S cells [33], all of them characterized by a low intrinsic activation (ratio p-Akt/total Akt lower than 1) of this signaling pathway (Figure S1). The gene discussed is AKT1; the disease is triple-negative breast carcinoma.